


1



2



3

Molecular allergen nomenclature

ALLERGEN NOMENCLATURE
WHO/IUIS Allergen Nomenclature Sub-Committee
Financial contribution from IUIS, EAACI, and AAAAI organizations

www.allergen.org

Genus species number

Dermatophagoides farinae 2nd allergen = Der f 2
Phleum pratense 1st allergen = Phl p 1

4

Content

- 1 The PAX for Dogs in numbers (2022-2024)
- 2 New findings on house dust mite allergens
- 3 Timing your sampling
- 4 About CCDs

5



6

nextmune **MAD** X
MACRO ARRAY DIAGNOSTICS

PAX
pet allergy xplorer

7

Nextmune PAX with MAD X technology **PAX**
pet allergy xplorer

- EP automated quantitative multiplex macroarray with cartridges containing up to 300 allergen-covered nanoparticles:
- EP one-third of "classical" extracts
- EP two-thirds of molecular components
- EP dogs: January 2023
- EP horses: September 2023
- EP cats: January 2024

8

Sensitization rates (2022 - 2024)

PAX (versions 22.2 and 23.1)
pet allergy xplorer

anti-IgE:	5.91
# environmental spots:	125 (60 ≠ species)
# venom spots:	13 (5 ≠ species)
# food spots:	98 (30 ≠ species)
# possible results:	236 (extracts + components)

9

Sensitization rates (2022 - 2024)

PAX (version 22.2)
pet allergy xplorer

anti-IgE:	5.91
# environmental spots:	125 (60 ≠ species)
# venom spots:	13 (5 ≠ species)
# food spots:	98 (30 ≠ species)
# possible results:	236 (extracts + components)
# dogs tested:	60 130
% positive:	92%
% IT-treatable:	85%
avg allergens IT:	3,8 - 9,7

10

Sensitization rates in Nextmune laboratories

	Avacta 5.91 mAb	HESKA FcεRIα	alergovet 4H4 mAb
anti-IgE:	5.91 mAb	FcεRIα	4H4 mAb
# environmental allergens:	38	24	34
# venom allergens:	0	0	0
# food allergens:	0	0	-
# possible results:	38	24	34
# dogs tested:	2 460	1 165	4 972
% positives:	74%	99%	87%
% IT treatable:	74%	99%	87%
avg allergens IT:	4,0	7,1	4,8

11

Sensitization rates between PAX and MAC test

	5.91 mAb (2022-2024)	mAb cocktail (MAC) (2016-2022)
anti-IgE:	5.91 mAb (2022-2024)	mAb cocktail (MAC) (2016-2022)
# dogs tested:	60 130	25 451
% with ≥ 1 positive:	85.1%	75.6%
% with ≥ 1 mite positive:	81.7%*	67.9%
% Der f positive:	73.5%	63.6%
% with ≥ 1 pollen positive:	36.9%	39.8%

* 2024 only
(Drouot, Vet Dermatol 2024)

12

Top 20 sensitizations (2022-2024) (97 841)  

1. Der f	66.9%	11. Api m 10	10.5%
2. Api m 1	20.8%	12. Amb a	10.4%
3. Api m	18.1%	13. Bos d 6	9.9%
4. Tyr p	15.8%	14. Par j 2	9.4%
5. Ves v 5	15.7%	14. Ves v	9.4%
6. Ves v 1	14.2%	16. Ovi a_meat	9.2%
7. Api m 3	14.1%	17. Cte f 1	8.6%
8. Tyr p 2	13.8%	18. Pol d 5	7.1%
9. Api m 2	10.7%	19. Par j	7.0%
10. Aca s	10.6%	20. Ave s	6.5%

versions 22.2 23.1 24.1 

13

Top 20 sensitizations (2022-2024) (97 841)  

 1. Der f	66.9%*	11. Api m 10	10.5%
2. Api m 1	20.8%	12. Amb a	10.4%
3. Api m	18.1%	13. Bos d 6	9.9%
4. Tyr p	15.8%	14. Par j 2	9.4%
5. Ves v 5	15.7%	14. Ves v	9.4%
6. Ves v 1	14.2%	16. Ovi a_meat	9.2%
7. Api m 3	14.1%	17. Cte f 1	8.6%
8. Tyr p 2	13.8%	18. Pol d 5	7.1%
9. Api m 2	10.7%	19. Par j	7.0%
10. Aca s	10.6%	20. Ave s	6.5%

versions 22.2 23.1 24.1 

14

Top 20 sensitizations (2022-2024) (97 841)  

1. Der f	66.9%	11. Api m 10	10.5%
 2. Api m 1	20.8%	12. Amb a	10.4%
3. Api m	18.1%	13. Bos d 6	9.9%
 4. Tyr p	15.8%	14. Par j 2	9.4%
5. Ves v 5	15.7%	14. Ves v	9.4%
6. Ves v 1	14.2%	16. Ovi a_meat	9.2%
7. Api m 3	14.1%	17. Cte f 1	8.6%
8. Tyr p 2	13.8%	18. Pol d 5	7.1%
9. Api m 2	10.7%	19. Par j	7.0%
10. Aca s	10.6%	20. Ave s	6.5%

versions 22.2 23.1 24.1  

15

Top 20 sensitizations (2022-2024) (97 841)  

1. Der f	66.9%	11. Api m 10	10.5%
2. Api m 1	20.8%	12. Amb a	10.4%
3. Api m	18.1%	13. Bos d 6	9.9%
4. Tyr p	15.8%	14. Par j 2	9.4%
5. Ves v 5	15.7%	14. Ves v	9.4%
6. Ves v 1	14.2%	16. Ovi a_meat	9.2%
7. Api m 3	14.1%	17. Cte f 1	8.6%
8. Tyr p 2	13.8%	18. Pol d 5	7.1%
9. Api m 2	10.7%	19. Par j	7.0%
10. Aca s	10.6%	20. Ave s	6.5%

versions 22.2 23.1 24.1  

16

Top 20 sensitizations (2022-2024) (97 841)  

1. Der f	66.9%	11. Api m 10	10.5%
2. Api m 1	20.8%	12. Amb a	10.4%
3. Api m	18.1%	13. Bos d 6	9.9%
4. Tyr p	15.8%	14. Par j 2	9.4%
5. Ves v 5	15.7%	14. Ves v	9.4%
6. Ves v 1	14.2%	16. Ovi a_meat	9.2%
7. Api m 3	14.1%	17. Cte f 1	8.6%
8. Tyr p 2	13.8%	18. Pol d 5	7.1%
9. Api m 2	10.7%	19. Par j	7.0%
10. Aca s	10.6%	20. Ave s	6.5%

versions 22.2 23.1 24.1  

17

Top 20 sensitizations (2022-2024) (97 841)  

1. Der f	66.9%	11. Api m 10	10.5%
2. Api m 1	20.8%	12. Amb a	10.4%
3. Api m	18.1%	13. Bos d 6	9.9%
4. Tyr p	15.8%	14. Par j 2	9.4%
5. Ves v 5	15.7%	14. Ves v	9.4%
6. Ves v 1	14.2%	16. Ovi a_meat	9.2%
7. Api m 3	14.1%	17. Cte f 1	8.6%
8. Tyr p 2	13.8%	18. Pol d 5	7.1%
9. Api m 2	10.7%	19. Par j	7.0%
10. Aca s	10.6%	20. Ave s	6.5%

versions 22.2 23.1 24.1  

18



19



20

Mite extracts and components  version 24.1



Der f
Der f 2 Der f 1
Der f 15* Der f 18*
**without natural glycans*

Aca s
Tyr p **Lep d**
Tyr p 2 Lep d 2
Gly d 2

Blo t
Blo t 5 Blo t 21
Blo t 10

Der p
Der p 1 Der p 2
Der p 5 Der p 7 Der p 10
Der p 11 Der p 21
Der p 23

21

Main IgE reactivity to mite components 

60 130 sera from European dogs suspected of allergic diseases 

Der f 73.5 %
Der p 6.8 %

1. Der f 2	5.7 %	6. Der f 21	2.3 %	11. Der p 20	1.8 %
2. Der p 2	5.4 %	7. Der p 10	2.2 %	12. Der p 7	0.7 %
3. Der f 1	4.3 %	8. Der p 5	1.7 %	13. Der f 18	0.6 %
4. Der p 1	3.3 %	9. Der p 23	1.3 %		
5. Der p 11	2.5 %	10. Der f 15	1.0 %		

22

Main IgE reactivity to mite components 

60 130 sera from European dogs suspected of allergic diseases 

Der f 73.5 %
Der p 6.8 %

1. Der f 2	5.7 %	6. Der f 21	2.3 %	11. Der p 20	1.8 %
2. Der p 2	5.4 %	7. Der p 10	2.2 %	12. Der p 7	0.7 %
3. Der f 1	4.3 %	8. Der p 5	1.7 %	13. Der f 18	0.6 %
4. Der p 1	3.3 %	9. Der p 23	1.3 %		
5. Der p 11	2.5 %	10. Der f 15	1.0 %		

most prevalent sensitizations to mite group 1 and 2 allergens

23

Main IgE reactivity to mite components 


60 130 sera from European dogs suspected of allergic diseases 

Der f 73.5 %
Der p 6.8 %


1. Der f 2	5.7 %	6. Der f 21	2.3 %	11. Der p 20	1.8 %
2. Der p 2	5.4 %	7. Der p 10	2.2 %	12. Der p 7	0.7 %
3. Der f 1	4.3 %	8. Der p 5	1.7 %	13. Der f 18	0.6 %
4. Der p 1	3.3 %	9. Der p 23	1.3 %		
5. Der p 11	2.5 %	10. Der f 15	1.0 %		

most prevalent sensitizations to mite group 1 and 2 allergens
rare sensitizations to high-molecular-weight allergens without natural glycans


24




25




26




27



28



29



30

Why such a difference between Der f and Der p?

Dermatophagoides farinae
(but not to *D. pteronyssinus*)

Toxocara canis

31

Which allergens cross-react between Der f and Toxo c?

Der f 15
Zen-1
(Der f 18)

via glycans

larval mucins (TES)

Der f 10
Der f 11

via peptides

adults Toxo c 3
Toxo c 2

PAX is usually negative for Der f 15/18 as they don't have the natural glycans!

(Olivry, Vet Dermatol 2024)

32

Conclusions: mite allergens

- House dust and storage mites are **important sources of allergens in dogs and cats**, as in humans
- Mite group 1 and 2 allergens are those most often detected in the PAX
- Pay attention to **which mite group 2 allergen** your pet is sensitized!
- Sensitization to the Der f extract mostly reflects **cross-reaction with *Toxocara canis***
- What is the clinical relevance of this cross-reactivity?*

33



34


Common Beech (*Fagus sylvatica*)

Fag s 1
PR-10 family


Fag s 1 IgE seropositivity

Region	March Seropositivity (%)
NL	~55
UK	~10
ES	~10
US	~10


35




36




37




38




39



40



41



42

Conclusions: influence of seasons on test results

- ⚡ **Serum levels of specific IgE and sensitization rates may vary between seasons**
- ⚡ This fluctuation can be seen **not only with sensitizations to pollens but also with mites** whose reproduction rates vary with heat and humidity!
- ⚠ *Do not only pay attention to pollen levels in the air; **allergen exposure also likely occurs on the ground with deposited pollen!***
- ➔ **Test within 2-4 weeks after the beginning of a clinical flare!**

43



44

Protein glycosylation

plant protein N-glycans

- Fucose
- xylose
- GlcNAc
- mannose

Extracellular
Cytosol

(modified from Munkley, Nat Rev Urol 2016)

many proteins (and allergens) are glycosylated = **glycoproteins**

45

Complex N-glycans

bees wasps

MMF3 MMF3F6

plants

MMXF3 MUXF3

non-human mammals

modified from Dina 621 <https://commons.wikimedia.org/>

some plants and venom allergens carry complex N-glycans with **fucose ± xylose**
mammals have **lost the enzymes to add these fucose/xylose!**
➔ these glycans can be recognized as foreign and **targeted by IgE/IgG!**

46

IgE sensitization to pollens or *Hymenoptera* stings

IgE target the CCD
IgE target the peptide

Extracellular
Cytosol

(modified from Munkley, Nat Rev Urol 2016)

CCD-IgE arise in ~30-90% of dogs sensitized to pollen and venom allergens

47

IgE sensitization to pollens or *Hymenoptera* stings

CCD

IgE antibodies against peptide epitope
➔ potential clinical relevance

Protein

www.clinlabint.com

48

IgE sensitization to pollens or *Hymenoptera* stings

CCD

Protein

Anti-CCD IgE antibodies → mostly without clinical relevance

IgE antibodies against peptide epitope → potential clinical relevance

www.citabiolab.com

49

Limited biological activity of CCD-IgE

animals

MDPI

Article

Evaluating the Pathogenic Potential of IgE Targeting Cross-Reactive Carbohydrate Determinants in Dogs

Thierry Olivry ^{1,*}, Ana Mas Fontao ², Laura Widom ³ and Ralf S. Mueller ^{1,4}

¹ Nestmune AB, Riddargatan 19, SE-114-57 Stockholm, Sweden
² Nestmune Spain, Valentin Beato 24, 28037 Madrid, Spain; ana.mas@nestmune.com
³ Center for Clinical Veterinary Medicine, Ludwig-Maximilians-University Munich, 80539 Munich, Germany; lwidom@medizinische-klinder.klinik.de
⁴ Correspondence: thierry.olivry@nestmune.com (T.O.); r.mueller@lmu.de (R.S.M.)

<https://www.mdpi.com/2076-2615/14/22/3275> OPEN ACCESS

(Olivry, Animals 2024)

50

CCD-IgE blocking common strategy

pollen-sensitized patient: Y = anti-peptide IgE, Y = anti-CCD IgE

serum incubation with CCD-expressing protein

blocking of CCD-IgE = removal of false positives to plant allergens!

(modified from: Altmann, Allergo J Int 2016)

51

PAX: a unique CCD-blocking strategy

PAX pet allergy explorer

- 1 blocking of all sera with a CCD-expressing protein mix
- 2 PAX with 2 detectors of CCD blocking efficiency
- 3 if one or both CCD detectors > 100.00 ng/mL: → 2nd block with a high amount of a different CCD-expressing protein, then 2nd PAX, or → machine-learning algorithm
- 4 if one or both CCD detectors > 28.00 ng/mL: → disclosure statement of insufficient blocking of CCD-IgE

(Olivry, Vet Sciences 2024)

52

For more details on CCD blocking strategy

PAX pet allergy explorer

MDPI

Article

Validation of a Multiplex Molecular Macroarray for the Determination of Allergen-Specific IgE Sensitizations in Dogs

Thierry Olivry ^{1,*}, Ana Mas Fontao ², Martina Aumayr ³, Natalia Paulenka Ivanova ³, Georg Mitterer ³ and Christian Harwaneg ³

¹ Nestmune AB, Riddargatan 19, SE-114-56 Stockholm, Sweden
² Nestmune Spain, Valentin Beato 24, 28037 Madrid, Spain; ana.mas@nestmune.com
³ MacroArray Diagnostics, Lombökgasse 59, 1220 Vienna, Austria; aumayr@macroarraysdi.com (M.A.); ivanova@macroarraysdi.com (N.P.); mitterer@macroarraysdi.com (G.M.); harwaneg@macroarraysdi.com (C.H.)
 * Correspondence: thierry.olivry@nestmune.com

<https://www.mdpi.com/2306-7381/11/10/482> OPEN ACCESS

(Olivry, Vet Sci 2024)

53

Importance of an effective blocking of CCD-IgE

PAX pet allergy explorer


CCD detector	ng/ml	class
• CCD detector:	914	4
• Dac g:	76	1
• Fes p:	59	1
• Poo p:	47	1
• Sec c_pollen:	110	2
• nCry j1:	35	1
• nCup o1:	59	1
• Rum ajc:	116	2
• Ama r:	103	2
• Api m:	190	2

2nd CCD block

CCD detector	ng/ml	class
• CCD detector:	114	2
• Dac g:	25	0
• Fes p:	26	0
• Poo p:	23	0
• Sec c_pollen:	25	0
• nCry j1:	24	0
• nCup o1:	27	0
• Rum ajc:	23	0
• Ama r:	27	0
• Api m:	191	2

••• CCD-bearing extracts or components: 16 | ••• CCD-bearing extracts or components: 5 (4 venoms)

54



55

Conclusions: CCDs

- EF CCDs are present in **allergens from plants and *Hymenoptera*** venoms and **can trigger the production of CCD-IgE** in humans, dogs, cats, and horses
- EF **CCD-IgE are not pathogenic in humans and dogs**
- EF The **PAX has a unique CCD-IgE blocking strategy** with a detection of the efficiency of that blocking
- EF **Four commercial IgE serological ELISA tests have insufficient CCD-IgE blocking** and report false positive sensitizations to pollen extracts

56

Conclusions: What did we cover today?


- EF The PAX allows for the **identification of unique sensitization patterns**
- EF The **main mite allergens (so far) are those of groups 1 and 2**
- EF **Mite group 2 allergens could be great indicators of the primary-sensitizing mites**
- EF The **high molecular weight allergens cross-react with *Toxocara canis***
- EF The **timing of sample collection can impact the detection of sensitization** to pollen (and also other) allergens

57

Conclusions: What did we cover today?

- EF CCDs are present in **allergens from plants and *Hymenoptera*** venoms and **can trigger the production of CCD-IgE** in a high proportion of humans, dogs, cats, and horses
- EF **CCD-IgE are not pathogenic in humans and dogs**
- EF **Insufficient blocking of CCD-IgE in serological tests leads to false positive to plant-based extracts and native components**
 - EF *The chosen serological test must have means to detect the efficiency of CCD-IgE blocking!*

58



59